中恆集團(600252.SH):製藥新基地三期(粉針劑車間〔三期〕)現正式投產
格隆匯12月19日丨中恆集團(600252.SH)公佈,募集資金投資項目“製藥新基地三期(粉針劑車間〔三期〕及固體制劑車間〔二期〕)項目”之“製藥新基地三期(粉針劑車間〔三期〕)”已完成工程建設、生產線設備調試、試產等前期工作,並已取得了藥品生產許可證,目前已具備投產條件,現正式投產。
此次募投項目部分投產後,將增加公司產品注射用血栓通(凍幹)的產能,提升注射用血栓通(凍幹)的生產技術水平與過程質量控制能力,增強公司的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.